Citius Oncology reports LYMPHIR order growth in fiscal Q3 2026, expands sales force

Citius Oncology, Inc., majority-owned by Citius Pharmaceuticals, Inc., reported fiscal third quarter 2026 results on August 14, 2026 for the period ended June 30, 2026. Chairman and CEO Leonard Mazur said institutional vial orders grew 31% sequentially, from 708 in the quarter ended March 31, 2026 to 926 in the quarter ended June 30, 2026.¹ He added that in July institutions ordered 383 vials from wholesalers, the largest order month to date, reflecting a 25% increase over the prior quarter's monthly average order¹, and that 44 institutions have prescribed and ordered LYMPHIR¹ to date.

On the commercial buildout, the company said in August, its full 29-person-strong commercial and medical affairs organizations expanded to nationwide coverage¹, and it is targeting formulary inclusion at 100 priority institutions by year-end¹. The field expansion was executed by the Company's exclusive commercialization partner, EVERSANA¹, adding 21 field-based professionals and eight medical science liaisons.

On the pipeline, the company highlighted two investigator-initiated Phase 1 studies: one combining LYMPHIR with pembrolizumab in gynecologic cancers showed 20.5 months of median progression-free survival among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21), with a 24% objective response rate overall and 33% ORR in relapsed or refractory endometrial cancer¹. A separate study of LYMPHIR before CAR-T therapy in high-risk relapsed or refractory DLBCL reported 86% ORR, including 57% complete response and 29% partial response, with no dose-limiting toxicities observed¹.

Financially, the company reported cash and cash equivalents of $16.6 million as of June 30, 2026¹, having received approximately $9.7 million in net proceeds from warrant exercises and funded $10.0 million under the first tranche of a senior secured term loan facility of up to $25.0 million¹. Revenue was $1.5 million for the quarter and $7.1 million for the nine months ended June 30, 2026¹, against a net loss of $8.9 million for the quarter and $41.1 million for the nine months¹.